Journal
BLOOD
Volume 115, Issue 3, Pages 437-438Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2009-10-251249
Keywords
-
Categories
Ask authors/readers for more resources
In this issue of Blood, Byrd and colleagues report on the outcomes of a phase 1/2 study of anti-CD23 monoclonal antibody lumiliximab combined with FCR in patients with refractory/relapsed CLL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available